IRLAB Therapeutics AB’s Post

Are you "𝘁𝗵𝗶𝗻𝗸𝗶𝗻𝗴 𝗼𝘂𝘁𝘀𝗶𝗱𝗲 𝘁𝗵𝗲 𝗯𝗼𝘅” for your next preclinical study? At BioModels, we understand that not every preclinical program has a clearly defined path to IND. Sometimes projects require creative scientific thinking and model development to deliver the solutions needed to advance your asset. 𝗕𝗶𝗼𝗠𝗼𝗱𝗲𝗹𝘀 𝘀𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘇𝗲𝘀 𝗶𝗻 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗻𝗴 𝘁𝗼 𝗱𝗲𝘃𝗲𝗹𝗼𝗽 𝗰𝘂𝘀𝘁𝗼𝗺𝗶𝘇𝗲𝗱 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀. Whether you’re interested in… • Proof-of-concept experiments designed to validate novel targets • Approaches that have been described in the literature • The ability to model disease indications for which the current animal models are insufficient or do not exist …𝘁𝗵𝗲 𝗕𝗶𝗼𝗠𝗼𝗱𝗲𝗹𝘀 𝘁𝗲𝗮𝗺 𝗶𝘀 𝗵𝗲𝗿𝗲 𝘁𝗼 𝗯𝗿𝗶𝗻𝗴 𝘆𝗼𝘂𝗿 𝗶𝗱𝗲𝗮 𝗳𝗿𝗼𝗺 𝗰𝗼𝗻𝗰𝗲𝗽𝘁 𝘁𝗼 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗶𝗼𝗻. Visit www.BioModels.com and fill out the contact us form at the bottom of the page to start the conversation! 

🔬 Just Released: OniX OnPoint Issue #11 - Week 11, 2024 Excited to share our latest deep dive into groundbreaking biotech innovations! This week's issue spotlights crucial developments in TREM2 research and neurodegenerative diseases. Highlights include: - Discovery of Aplp1 and Lag3 interaction as a new target in α-synucleinopathies - AI-predicted structures unlocking new drug discovery opportunities for protein kinases - Insights into how glycolytic flux drives retinal progenitor differentiation via Wnt signaling - Identification of specialized immune cells in metastatic cancer spread - Innovative use of placenta donations for healing burns and wounds Our comprehensive analysis covers everything from technology transfer and sponsored projects to startup innovations and the latest research breakthroughs. Want More? Join Our Community! https://lnkd.in/edUVWht9 🎉 Excited about these breakthroughs? There's so much more to explore! - Sign up for our newsletter: Get free access to our Table of Contents and stay in the loop with the latest biotech trends. - Go Premium: Unlock full access to all our in-depth content with our yearly plan. Don't miss out on the cutting-edge insights that could shape the future of biotech. Join us today and be part of the innovation journey! 🔗 Explore our plans and start your biotech adventure #Biotech #Innovation #Research #Neuroscience #DrugDiscovery #TREM2 #BiotechNews

Thrilled to share something that has been a labor of love for my team: the launch of QIAGEN Biomedical KB-AI. This new platform opens access to over 640 million biomedical relationships, spanning genes, diseases, drugs, and beyond. Here are a few things to point out: - Comprehensive Coverage: providing millions of gene-disease-drug causal links. - Semantic Relationships: Uncover those elusive needles in the haystack, crucial for advancing rare disease research and oncology. - Speed and Precision: Dramatically reduce hypothesis testing times towards new therapeutic discoveries. This separates itself from our manually curated Biomedical KB-HD product, by employing generative AI methods to curate data from a plethora of publications and databases. To know more, check here: https://lnkd.in/gJiNsqrU #QIAGEN #BiomedicalKnowledge #AIDrugDiscovery #drugdiscovery #drugdevelopment The announcement is available here: https://lnkd.in/gkHRg946

At the close of Frontiers Health 2024, we had the pleasure of speaking with Luca Quagliata, PhD, BCMAS, COA, VP and Global Head of Medical and Scientific Affairs from Thermo Fisher Scientific, about the advancements in precision medicine. 🎙️ "Amid significant geographical variations in the adoption of omics technologies, the past ten years have seen an immense accumulation of data. Now, with a critical mass of information at our disposal, the focus shifts to mining key insights from this wealth of data." - said Quagliata. There's now a strong need for a quantum leap from research to diagnostic. Discover more in this article authored by Sara Scarpinati, Marketing Ecosystem Manager at EVERSANA: https://lnkd.in/d5MR73W3

Follow us and our Cluster member Miltenyi Biotec on the exciting journey from target validation via proof of principle in small scale to clinical scale: In three hybrid sessions and a hands-on demo day on the CliniMACS Prodigy we will focus on different stages of the development of cell- and genetherapies in our seminar series “From target validation to clinical application”. As an expert in the field,Miltenyi Biotec will help you set up your own experiments with exclusive tips and tricks based on more than 10 years of experience. In our first seminar we will talk about the potential of Spatial Biology for target identification and validation as well as possibilities for patient stratification using the MACSima Platform. Our second and third seminar will focus on how to translate a cellular therapy approach from the early benchtop experiments to a clinical scale production. 

AlveoGene’s Mission is to transform respiratory disease outcomes using inhaled gene therapy.     Our #InGenuiTy® platform enables us to deliver our proprietary self-inactivating lentiviral vector based products directly to the lung via nebulisation treating disease locally, efficiently, and safely where it’s clinical impact and patient benefit can be the greatest. We focus on respiratory diseases of high value and unmet medical need, developing first-in-class and best-in-class products including Alpha-1 Antitrypsin Deficiency (AATD), Neonatal Profound Surfactant Protein Deficiencies (SP-B and ABCA3), and Idiopathic pulmonary Fibrosis (IPF). Ahead of Rare Disease Day this Thursday, please join the Oxford-Harrington 2024 Rare Disease Day Webinar hosted on Wednesday, Feb. 28, 2024, from 10:00 – 11:00 a.m. EST/3:00 p.m. to 4:00 p.m. GMT by clicking the link below. @HarringtonDI_UH @OHRareDisease

Looking forward to seeing some known faces and meeting some new ones! Investing? How commercially viable is the science? What are the product development/CMC and regulatory risks? What is the competitive landscape? Fundraising? Does your pitch deck and data room position your company to be as investable as possible? Promising non-clinical data? How to turn that into a commercial product? What is the best product development and regulatory strategy? Growing pains? Addressing the various resource gaps in regulatory affairs, regulatory operations, clinical operations, clinical and medical affairs, regulatory and medical writing and many more as you transition the product from one phase to another! It has been great to work with innovators and the leaders to help them advance their asset and materialize the vision! Looking forward to connecting further to brainstorm solutions with you! #TexasLifeSciencesSummit #CPRIT #THBI

⭐ October is #NationalWomensSmallBusinessMonth, a time to celebrate trailblazing women who are making a positive impact in our community. We're excited to spotlight Spring Behrouz, CEO of Vincere Biosciences. 🔬Vincere Biosciences aims to conquer age-related diseases through the development of small molecule therapeutics empowered by a suite of computational tools alongside traditional biology and drug discovery expertise. These small molecules have the potential to become the world's first-ever medicines capable of slowing down or even halting the progression of debilitating conditions like Parkinson's disease and other age-related diseases. ➡️ Learn more about Vincere Biosciences: bit.ly/3NCtq5G

In the journey of drug discovery, selecting the right model is not just a step—it's a leap toward success. Our CEO, Jos Joore, and Director of Biology Discovery, Lenie van den Broek, delve into the limitations of traditional disease models in this video. Watch and learn how MIMETAS' physiologically-relevant 3D disease models can transform your drug discovery process by enabling more accurate clinical predictions. 🔍 Discover how our offerings can accelerate your projects. Watch now and explore our offerings: https://lnkd.in/evue8i28 #DrugDiscovery #ClinicalAccuracy #PredictiveModels

In the journey of drug discovery, selecting the right model is not just a step—it's a leap toward success. Our CEO, Jos Joore, and Director of Biology Discovery, Lenie van den Broek, delve into the limitations of traditional disease models in this video. Watch and learn how MIMETAS' physiologically-relevant 3D disease models can transform your drug discovery process by enabling more accurate clinical predictions. 🔍 Discover how our offerings can accelerate your projects. Watch now and explore our offerings: https://lnkd.in/evue8i28 #DrugDiscovery #ClinicalAccuracy #PredictiveModels